Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

26.60 +0.31 (+1.18%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma Plc Cl A

< Previous 1 2 3 4 5 6 7 Next >
Royalty Pharma Earnings Perspective: Return On Capital Employed
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters. 
Via Benzinga
Executives Sell Around $325M Of 3 Stocks
Gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple
Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
Upgrades 
Via Benzinga
Expert Ratings for Royalty Pharma
Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter: 
Via Benzinga
Royalty Pharma: Q1 Earnings Insights
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap: Royalty Pharma Q1 Earnings
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
How To Attend Royalty Pharma Q1 2022 Earnings Conference Call
Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
Expedia And 3 Other Stocks Insiders Are Selling
Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or... 
Via Benzinga
Hopeful Golden Cross Forms On Royalty Pharma's Chart
If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,... 
Via Benzinga
Looking Into Royalty Pharma's Return On Capital Employed
According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67%... 
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital... 
Via Benzinga
DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney Merger
Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney. 
Via InvestorPlace
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market... 
Via Benzinga
Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE: 
Via Benzinga
BioCryst Shares Gain As Royalty Pharma Buys Additional Interests In BCX9930, Orladeyo
Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals... 
Via Benzinga
Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) stock rose 48.27% to $12.47 during Tuesday's pre-market session. The market value of their outstanding shares is at $612.8... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday. 
Via InvestorPlace
36 Stocks Moving in Tuesday's Pre-Market Session
Gainers BIMI International Medical Inc. (NASDAQ: BIMI) rose 63.9% to $1.07 in pre-market trading as the company reported a narrower Q3 loss. Kezar Life Sciences, Inc. (NASDAQ:... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Kezar Life Sciences (NASDAQ:KZR) s... 
Via Benzinga
Royal Pharma (RPRX) Q3 2021 Earnings Call Transcript
RPRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021
Upgrades For Preferred Bank (NASDAQ: 
Via Benzinga
AstraZeneca's Two Asthma Trials Meet Primary Endpoints
Avillion LLP announces positive topline results from the MANDALA and DENALI Phase 3 trials of PT027 in asthma patients. PT027 is an inhaled, fixed-dose combination of... 
Via Benzinga
Cramer Gives His Opinion On Applied Materials, Coinbase And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said Applied Materials, Inc. (NASDAQ: AMAT) reported an excellent quarter. People who were selling the stock didn... 
Via Benzinga
Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma
Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors. The Company was founded in 1996 and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.